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The efficacy of combining immunization with human immunodeficiency vitus type 1 (HIV-1) DNA and HIV-1 recombinant
proteins to obtain protection from chimeric simian/human immunodeficiency virus (SHIV) was determined. Four cynomolgus
monkeys received four gene-gun immunizations intraepidermally of plasmid DNA encoding HIV-1LAI env (gp160), gag, tat, nef,
and rev proteins. Ten micrograms of DNA was used per immunization. The animals were boosted twice intramuscularly with
50 mg of HIV-1LAI Env (MicroGeneSys), Gag, Tat, Nef, and Rev recombinant proteins mixed in Ribi adjuvant. The antibody
responses were amplified following the administration of the recombinant subunit boosts. One month after the final subunit
immunization, the vaccinated animals together with four control animals were challenged intravenously with 10 monkey
infectious doses of SHIV that expresses the env, tat and rev genes of HIV-1 and gag and nef from SIV. However, only low titers
of neutralizing antibodies were present at the day of challenge. The consecutive HIV-1 DNA and recombinant protein
immunizations induced B- and T-cell responses but not protection against SHIV replication nor reduction of the viral load.
© 1998 Academic Press
INTRODUCTION
To design an effective vaccine to protect people from
infection with human immunodeficiency virus (HIV) and
to protect against AIDS are high priorities in controlling
the epidemic. Preclinical vaccine studies in nonhuman
primates are important for identifying which vaccine can-
didates should proceed to human clinical trials. Chimeric
simian/human immunodeficiency viruses (SHIVs) in
which the SIV env gene has been replaced with the env
gene of various HIV-1 strains are becoming increasingly
important for assessing the potential efficacy of candi-
date HIV-1 vaccines (Li et al., 1992).
To date the most potent protection against simian
immunodeficiency virus (SIV) has been obtained with live
attenuated vaccines (for a review, see Putkonen et al.,
1996). However, a live attenuated HIV-1 vaccine in hu-
mans is associated with a number of safety concerns.
A novel approach to immunization is the induction of
immune responses against an antigenic protein ex-
pressed in vivo from an introduced gene (Vogel et al.,
1995). This so-called DNA vaccination is attractive be-
cause it mimics the effects of live attenuated viral vac-
cines in that both humoral and cellular immune re-
sponses can be induced (Okuda et al., 1995, Wang et al.,
1995a; Yasutumi et al., 1996).
Immunization with DNA in various animal models has
been shown to be successful in generating protective
immunity against, i.e., influenza (Fynan et al., 1993; Ulmer
et al., 1993), rabies virus (Xiang et al., 1994), herpes
simplex virus (Bourne et al., 1996), and murine cytomeg-
alovirus (Gonza´lez Armas et al., 1996). In these various
virus models, DNA vaccines have provided protection
against disease but not against infection. Limited work
has been done using DNA to raise protective immune
responses against primate lentiviruses. Wang and col-
laborators (Wang et al., 1995) have shown that immuni-
zation with HIV-1 DNA in macaques achieved some re-
duction in postchallenge viral load with a SHIV challenge
given intravenously. Boyer et al. (1997) have reported
protection against establishment of HIV-1 infection in two
chimpanzees vaccinated with HIV-1 DNA. In a simian
immunodeficiency virus vaccine trial in rhesus ma-
caques, a DNA vaccine failed to achieve protection
against disease (Lu et al., 1996). In HIV-1-infected hu-
mans, HIV DNA representing regulatory genes were re-
cently shown to induce new and increased levels of
HIV-specific cytotoxicity (Calarota et al., 1998).
Four reports provide indications of a synergistic rela-
tionship between genetic and recombinant subunit-
based immunization (Leong et al., 1995; Fuller et al.,
1996, 1997; Letvin et al., 1997). By using a combined DNA
1 To whom correspondence and reprint requests should be ad-
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plus protein immunization regime, enhanced immune
responses were induced. Improved responses were
seen even when the DNA was only weakly immuno-
genic. The present study addresses whether immuniza-
tion with HIV-1 DNA followed by subunit boosts confers
immune responses and protective benefit against a SHIV
challenge.
RESULTS
Immune responses in vaccinated monkeys
Serum IgG responses were low to moderate after the
DNA immunizations but rapidly increased after the pro-
tein boosts (Table 1A, Fig. 1). After the protein boosts, the
four vaccinees had high antibody responses to structural
as well as to regulatory proteins, but anti-rev IgG re-
mained low in two animals. Development of HIV-1 virus
neutralizing antibodies was detected only after protein
immunizations and was seen in all the vaccinees. The
four vaccinated monkeys developed neutralizing anti-
bodies to HIV-1LAI with IC50 titers ranging from 40 to 220
(Table 2). Two animals showed IC90 titers of 40 in one
animal (C85) and 70 in another (C91). Neutralizing anti-
bodies against the primary clade B isolate 6794 was
detected in Monkey C85 only. SHIV-neutralizing antibod-
ies were seen in three vaccinees (C85, C90, and C91).
It was not possible to detect any specific CTL against
HIV-1 Env, HIV-1 Nef, nor against SIV Nef before SHIV
challenge.
T cell proliferation to all protein antigens and synthetic
peptides representing the regulatory proteins were per-
formed once before and nine times during immunizations
and seven times after SHIV challenge (Table 1B). The
highest responses were seen during the DNA immuni-
zations and after SHIV challenge (Fig. 2). Both structural
and regulatory antigens contributed to the anti-HIV-spe-
cific reactivities. Macaques C90 and C91 had the broad-
est reactivities, while Macaque C85 had high stimulation
indexes. Among control animals an unspecific prolifera-
tive reaction was seen with the Nef antigen (Table 1B).
Local reactions were observed as a skin rash in two of
the vaccinees (C90 and C91) This reaction was localized
in the groin of the site of DNA-immunization with a size
of approximately 1.5 3 1.5 cm. These reactions increased
in size to 3 3 5 cm following the protein immunizations,
which were given intramuscularly. A skin biopsy con-
tained inflammatory cells with no atypia. None of the two
other vaccinated monkeys nor the four control DNA im-
TABLE 1
A. HIV-1 IgG Titers in Four Cynomolgus Monkeys after Immunizations with HIV-1 DNA
and Following Recombinant Subunit Booster Immunizations
Monkey no.
Two weeks after the 4th DNA immunization Four weeks after two HIV-1 protein immunizationsa
gp160 p24 Tat Nef Rev gp160 p24 Tat Nef Rev
C84 ,50 300 450 500 300 9500 5800 1200 500 ,50
C85 360 410 ,50 200 200 .104 8200 .104 6000 4000
C90 300 ,50 ,50 125 ,50 .104 1000 .104 4000 210
C91 140 ,50 ,50 ,50 ,50 .104 .104 .104 1050 ,50
a Sera were taken 4 weeks after HIV-1 protein immunizations.
B. T-cell Proliferation against HIV-1 Antigens and Regulatory Protein Peptides
Monkey no.
Frequency of responses after DNA
immunizations and protein boost
Frequency of responses after SHIV
challenge immunizationsa
gp160 p24 Tat 1 Pb Nef 1 P Rev 1 P gp160 p24 Tat 1 P Nef 1 P Rev 1 P
Vaccine
C84 2/9 2/9 4/9 5/9 6/9 4/7 3/7 6/7 7/7 3/7
C85 0/9 2/9 4/9 5/9 5/9 4/7 3/7 4/7 5/7 5/7
C90 3/9 3/9 4/9 7/9 2/9 2/7 2/7 2/7 6/7 1/7
C91 1/9 2/9 3/9 4/9 5/9 4/7 4/7 3/7 5/7 3/7
Control
C23 0/9 1/9 1/9 5/9 1/9 0/7 0/7 1/7 5/7 0/7
C28 1/9 0/9 1/9 5/9 2/9 0/7 0/7 2/7 2/7 1/7
C88 0/9 0/9 3/9 3/9 1/9 0/7 1/7 2/7 1/7 1/7
C89 0/9 0/9 1/9 0/9 1/9 2/7 3/7 3/7 7/7 4/7
a Number of positive SI of number of tests.
b P, synthetic peptide.
294 PUTKONEN ET AL.
munized monkeys developed skin reactions at the sites
of immunization.
HIV-1-specific B-cell IgG synthesis in vitro
Two DNA plasmid immunizations were required be-
fore HIV-1-specific IgG were produced by lymphoid cells
collected from blood. All four immunized macaques re-
sponded by developing B cells secreting IgG specifically
reactive with HIV-1 recombinant antigens. The highest
levels were directed against Nef and Tat, with the main
reactivity directed to the C-terminal region of Nef (aa
165–210) and to the central region of Tat (aa 31–65).
Following the HIV-1 protein immunizations, all vacci-
nated animals developed B cells secreting HIV-1-specific
FIG. 1. HIV-1 antigen specific serological responses in Monkey C84 (A), Monkey C85 (B), Monkey C90 (C), and Monkey C91 (D), before and during
immunizations and postchallenge. Serum IgG to HIV-1 gp160 and p24 as well as neutralizing antibody titers to HIV-1LAI (50 TCID50), primary isolate
6794 (40 TCID50) and SHIV (10 TCID50) are shown. DNA immunization time is indicated by * and protein boosts by P. SHIV challenge intravenously
was performed at Day 294 as indicated.
TABLE 2
HIV-1 Neutralization Titers of Serum from Four Cynomolgus Monkeys after Immunizations with HIV-1 DNA,
Recombinant Subunit Boosters and Post-SHIV Challenge
Monkey no.
Pre-SHIV challenge at time for challengea Four weeks post-SHIV challenge
HIV-1LAI
6794
IC50
SHIV HIV-1LAI
6794
IC50
SHIV
IC90 IC50 IC90 IC50 IC90 IC50 IC90 IC50
C84 ,20 180 ,20 ,20 ,20 540 1080 ,20 60 360
C85 40 100 70 20 60 180 450 80 60 540
C90 ,20 40 ,20 ,20 20 80 360 ,20 20 180
C91 70 220 ,20 20 60 200 750 ,20 20 60
a Sera were taken 4 weeks after HIV-1 protein immunizations; this also was the time of challenge with SHIV. Inhibiting serum virus neutralisation
concentrations (IC) IC50 and IC90 titers are shown.
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IgG to all HIV-1 antigens except the Rev protein. Lym-
phoid cells taken from the control monkeys remained
negative.
Intravenous challenge with SHIV
After SHIV challenge, virus was isolated from PBMCs
of all vaccinated monkeys as well as from control DNA
immunized controls. One of the vaccinated animals (C85)
had the lowest post challenge levels of infected PBMCs
of any challenged animal (Fig. 3). His infection was
detectable by virus isolation at Day 14 and thereafter only
by PCR. At 14 days postchallenge, the concentration of
plasma p26 antigen was low in three of four vaccinated
animals and in two of four in the control group (Fig. 4).
FIG 2. (A–D) Kinetics of the HIV-1 and baculovirus control antigen specific T-cell proliferation in vitro with peripheral blood cells from vaccinated
Monkeys C84, C85, C90, and C91 during immunizations and after challenge. (E and F) T-cell proliferation in vitro with peripheral blood cells from two
representative control monkeys, C23 and C89, before and after challenge. DNA immunization is indicated by * and protein boosts by P. Control
monkeys received DNA plasmid without any inserted gene and Ribi adjuvant boosts without protein. SHIV challenge intravenously was performed
at Day 294 as indicated.
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Despite the early reductions in viral load, the vaccinated
animals did not clear their infections. The trial was ter-
minated 8 months postchallenge.
Immune responses to SHIV challenge
The humoral and cellular immune responses were
characterized also after challenge. Here responses were
measured to both HIV-1 and HIV-2 antigens because SIV,
SHIV, and HIV-2 are closely related. In the vaccine group,
anamnestic humoral and cellular immune responses ap-
peared to both HIV-1 and HIV-2 after SHIV inoculation
(Table 3). After SHIV challenge all four control monkeys
made primary anti-SHIV antibodies by 12 weeks.
The four vaccinated animals showed an increase of
neutralizing antibody titers to HIV-1LAI from 40–220 to
360–1080 due to the SHIV infection (Fig. 1). A similar
effect was also seen in neutralizing titers against SHIV. In
all control animals, neutralizing antibodies remained un-
detectable until 2 months post-SHIV challenge, when all
four developed low titers against HIV-1 or against SHIV.
At 1 month postchallenge, CTL activity was not detected
in the control group, but low levels of CD81-dependent
HIV-1env and SIVnef specific CTL responses were iden-
tified in three immunized monkeys (C85, C90, and C91).
DISCUSSION
A low dose of epidermally given DNA vaccine in com-
bination with recombinant subunit proteins had a poor
impact on SHIV replication. There was no clear differ-
ence after challenge in the virus burden of the immu-
nized monkeys compared with the controls. Both the
protein boosts and particularly the SHIV challenge had
significant effects in increasing anamnestic humoral im-
mune responses.
Our inability to induce sterilizing immunity was disap-
pointing. The slight reduction of viral recovery in one
vaccinated monkey and the weak immune responses
after the DNA immunizations were probably due to the
small doses of DNA used (10 mg per immunization).
Our study should be compared with those using
higher doses of DNA. For example, good antibody titers
have been observed in chimpanzees injected with 2 mg
of plasmid DNA encoding the major hepatitis B envelope
proteins (Davis et al., 1996). Letvin and collaborators
(Letvin et al., 1997) have demonstrated that milligram
doses of HIV-1 DNA combined with HIV envelope boosts
protected monkeys from intravenous challenge with a
nonpathogenic SHIV. Chimpanzees injected intramuscu-
larly six times with 100 mg and twice with 1 mg of HIV-1
env and gag/pol DNA showed low-level env-specific
neutralizing antibodies, and low levels of Env and gag/
pol specific cytotoxicity. They were protected from HIV-1
infection (Boyer et al., 1997). In HIV-infected humans,
repeated 100 mg doses of HIV-1 DNA have been dem-
onstrated to increase the HIV-specific cytotoxicity (Ca-
larota et al., 1998).
During the DNA immunization, the antibody titers in
serum were low in three of the four vaccinees. However,
all animals in the vaccine group that were seronegative
had B cells that were capable of secreting specific anti-
bodies in vitro upon antigen stimulation. This indicates
that B-cell memory was induced in all vaccinated ani-
mals. The gene-gun delivery of DNA was effective in
priming for the induction of high-titered antibody re-
sponses when followed by subunit booster immuniza-
tions. Neutralizing antibodies were induced, but the lev-
els were low before challenge. In Vaccinee C85 the
neutralizing antibody titer was not better than in the other
animals, but when tested against a primary isolate, this
was the only animal serum capable of neutralizing a
primary isolate (Fig. 1B, Table 2).
The reason for failure of inducing detectable CTLs
after vaccination in the present study is not known but
may be due to the low dose of DNA used or the mode of
administration. Even in high-dose DNA immunized ani-
mals it seems difficult to obtain .10% of specific target
cell lysis by CTL (Boyer et al., 1997). T-cell proliferations
were high following the DNA immunizations. Recall T-cell
FIG. 4. Concentration of plasma p26 viral antigen at 9 and 14 days
following SHIV challenge.
FIG. 3. Cell-associated viral loads at 1, 2, and 3 months postinfection
(m.p.i) of cynomolgus monkeys following SHIV challenge.
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proliferation responses were seen after SHIV challenge,
indicating that T-cell memory was induced by the DNA
immunizations. This could explain the local skin delayed
type hypersensitivity-like reaction noticed in two of four
vaccinees.
The present study failed to demonstrate protection
against infection when the challenge inoculum was ad-
ministered intravenously. Protection may be more easily
obtained against mucosal than systemic challenge (Que-
sada-Rolander et al., 1996; Putkonen et al., 1997). The
major mode of HIV transmission worldwide is through
mucosal transmission, and we have recently demon-
strated efficacy of mucosal DNA administration (Asakura
et al., 1997). Studies to improve the efficacy of DNA
immunization by optimizing humoral and cell-mediated
immune responses particularly at mucosal surfaces are
therefore warranted.
MATERIALS AND METHODS
Vaccine DNAs
Plasmids carrying HIV-1LAI regulatory genes rev, tat,
and nef and structural genes p37 (gag) and gp 160 (env)
controlled by the human immediate early cytomegalovi-
rus promoter were used (Wahren et al., 1995; Hinkula et
al., 1997). The HIV-1gag-encoding plasmid produces a
37-kDa protein consisting of p17gag and p24gag.
Recombinant proteins and synthetic peptides
The recombinant proteins were baculovirus expressed
HIV-1LAI gp160 and p24 and control antigen (MicroGeneSys
Inc., Meriden, CT), Rev, Tat, and Nef (Wahren et al., 1995,
1996; Hinkula et al., 1997). Recombinant Nef was kindly
donated by Drs. Birgit Kohleisen and Volker Erfle (GSF,
Forschungscentrum Neuherberg, Oberschlossheim, Ger-
many) and Tat by Dr. J. Karn (Medical Research Council,
UK). Synthetic peptides were derived from the three regu-
latory proteins, Rev, Tat, and Nef of the HIV-1LAI strain, and
all peptides were 20-mers with a 5-aa overlap (Hinkula et
al., 1997).
Viruses
Chimeric SIVmac 239, also called SHIV-4, expressing
the env, rev, and tat of HIV-1IIIB (LAI strain HXBc2) (Li et
al., 1992) was a kind gift from Drs. J. Li and J. Sodroski
(Dana-Farber Cancer Institute, Boston, MA). This SHIV
chimera was grown on cynomolgus monkey peripheral
blood mononuclear cells, and a cell-free virus stock was
subsequently prepared. The infectious dose of the SHIV
stock was determined by in vivo titration in cynomolgus
monkeys (Berglund et al., 1997). The stock contained
approximately 104 100% monkey infectious doses
(MID100) of SHIV/ml. Stocks of HIV-1LAI and HIV-1SF2 were
grown in human peripheral blood mononuclear cells
(PBMC).
Animals, immunization, and virus challenge
Two groups of four cynomolgus monkeys (Macaca
fascicularis) were used. Four monkeys (C84, C85, C90,
and C91) received DNA immunizations by using a gene
gun (Accell, Geniva, Middleton, WI) to deliver DNA-
TABLE 3
Antibody Responses after SHIV Challenge
Group ELISA
Antibody titers at
SHIV
challenge
2 weeks
post challenge
1 month
post challenge
3 months
post challenge
Vaccine
C84 HIV-1LAI gp120 500 500 12,500 62,500
HIV-2 virions 500 2,500 62,500 12,500
C85 HIV-1LAI gp120 2,500 2,500 12,500 12,500
HIV-2 virions 2,500 2,500 12,500 2,500
C90 HIV-1LAI gp120 2,500 62,500 62,500 62,500
HIV-2 virions 2,500 12,500 62,500 12,500
C91 HIV-1LAI gp120 12,500 62,500 312,500 62,500
HIV-2 virions 2,500 12,500 62,500 12,500
Controls
C23 HIV-1LAI gp120 ,100 ,100 500 62,500
HIV-2 virions ,100 ,100 ,100 2,500
C28 HIV-1LAI gp120 ,100 ,100 ,100 12,500
HIV-2 virions ,100 ,100 2,500 2,500
C88 HIV-1LAI gp120 ,100 ,100 ,100 12,500
HIV-2 virions ,100 ,100 ,100 2,500
C89 HIV-1LAI gp120 ,100 ,100 ,100 32,500
HIV-2 virions ,100 ,100 ,100 500
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coated gold beads to the epidermis (Pertmer et al., 1995).
Four doses of plasmid DNA encoding HIV-1LAI Env
(gp160), Gag, Rev, Tat, and Nef proteins were given at 0,
1, 3, and 5 months. Ten micrograms of DNA was used per
immunization. By the 7th and the 9th month, the animals
were boosted intramuscularly with 50 mg HIV-1LAI gp160,
p24, Rev, Tat, and Nef recombinant proteins mixed with
Ribi adjuvant (Ribi, Immuno Chem Research Inc., Ham-
ilton, MO). Four control monkeys (C23, C28, C88, and
C89) received plasmid DNAs without inserts followed by
Ribi adjuvant but no proteins. One month following the
final subunit immunization, the vaccinated animals to-
gether with the four control animals were challenged
intravenously with 10 MID100 of SHIV.
Detection of humoral immune response in vivo
Antibody titers to native HIV-1LAI gp120 were deter-
mined by enzyme-linked immunosorbent assays
(ELISA) as previously described for HIV-2 gp125 (Nil-
sson et al., 1995). Antibodies to the HIV-1LAI recombi-
nant proteins and synthetic peptides representing the
antigens used for immunization were also determined
by ELISA. Microtiter plates (Nunc, Aarhus, Denmark)
were coated with the recombinant proteins at a con-
centration of 0.5 mg/ml or with the synthetic peptides
at 10 mg/ml (in 0.05 M carbonate buffer, pH 9.6).
Coated plates were kept at room temperature over-
night before use. The plates were blocked with 1%
bovine serum albumin (BSA) in phosphate-buffered
saline (PBS) for 60 min and washed twice in saline
with 0.05% Tween 20 before serial dilutions of animal
sera were added, 100 ml/well. Plates were incubated
for 2 h at 37°C, washed, and alkaline phosphatase
labeled goat anti-human IgG (Sigma, St. Louis, MA)
was added as tracer, 100 ml/well. One hundred micro-
liters per well of p-nitrophenylenediamine was used
as substrate for 30 min before the color development
was measured at OD 410 nm. The color reaction was
considered positive when the absorbance value was
above the mean of the negative controls 12 SD. Pre-
immunization sera from each animal were used as
negative controls.
Selected serum samples were tested for their ability to
neutralize HIV-1 infectivity in vitro. For the neutralization
assay, preimmune and postvaccination serum samples
were heat inactivated at 56°C for 30 min, and serial
twofold dilutions were prepared. Sera were diluted in
RPMI 1640 medium supplemented with 4 mM L-glu-
tamine, 50 IU/ml penicillin, 50 mg/ml streptomycin, and
10% inactivated fetal calf serum. Serum dilutions were
incubated with 40–60 tissue culture infectious doses
(TCID)50 of two HIV-1 strains LAI and 6794 or with 5
TCID50 of the SHIV strain used for challenge. Serum and
virus mixtures were kept at 37°C for 60 min before target
cells (human PHA-activated PBMC for the HIV-1 strains
and human C8166 lymphoid cells for the SHIV isolate)
were added, 100,000 cells/well. After 60 min at 37°C, the
cells were washed twice with 200 ml RPMI 1640 medium
(200 ml/well). The cells were cultured at 37°C in 5% CO2
for 3 days when 50% of the medium was exchanged. At
Day 6–7, the presence of HIV-1 p24 or SIV p26 antigen in
the culture fluid was measured by capture ELISA
(Sundqvist et al., 1989; Thorstensson et al., 1991). The
neutralizing titer was defined as the reciprocal of the
highest dilution resulting in 50 or 90% reduction (IC50–90)
of absorbance in comparison with serum samples col-
lected prior to immunization.
Detection of HIV-1 antibodies after in vitro stimulation
HIV-1 DNA-vaccinated monkeys without detectable
antibodies after immunization were tested for circulating
B cells capable of secreting HIV-1-specific antibodies
when stimulated in vitro with the antigens used for im-
munization. PBMCs (100,000/well in 200 ml RPMI 1640
supplemented with 5% inactivated fetal calf serum se-
rum) were cultured for 72 h in triplicate wells at 37°C in
96-well, flat-bottomed cell culture plates (Nunclon, Nunc)
with the antigens at concentrations of 1 mg/well. After
washing, the bound Ig was assayed by the ELISAs de-
scribed above.
Cellular immune response
T-cell stimulation. Peripheral blood cells (150,000
cells/well) were cultured for 6–7 days in RPMI 1640
supplemented with 4 mM L-glutamine, 50 IU/ml penicil-
line, 50 mg/ml streptomycin, and 10% human CMV neg-
ative AB1 serum in the presence of 0.1–1 mg antigen in
triplicate wells. Medium alone was used as negative
control, and phytohemagglutinin (PHA) was used as mi-
togen to measure unspecific cell stimulation. Fifty micro-
liters/well of tritium-labeled thymidine was added (1 mCi)
and cells were incubated for 5–6 h before the cells were
harvested and thymidine incorporation was measured in
a b counter. The stimulation index (SI) was calculated by
dividing the mean cpm values in triplicate wells of the
antigen stimulated wells with the mean cpm of medium
control wells. A more than fivefold SI with whole proteins
and a more than threefold SI with synthetic peptides was
considered positive (Hinkula et al., 1997; Calarota et al.,
1998).
The cytotoxic T lymphocyte (CTL) response was mea-
sured in a standard chromium release assay (Andersson
et al., 1996; Putkonen et al., 1997). Target cells were
autologous B-lymphoblastoid cell lines infected with 10
plaque forming units of recombinant vaccina virus ex-
pressing Env or Nef protein of HIV-1 or Nef protein of
SIVmac32(pJ5) (Rud et al., 1994). As a control, CD81 T
cells were depleted by use of antibodies on magnetic
Dynabeads (Dynal, Oslo, Norway).
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Postchallenge tests for infection
SHIV isolation was performed by cocultivation of mon-
key PBMCs with PHA-stimulated human PBMCs (Nils-
son et al., 1995). The viral load following SHIV challenge
in peripheral blood was determined by a limiting dilution
assay. Serial twofold dilutions of monkey PBMCs (start-
ing with 5 3 105 cells) were cocultivated with C8166 as
indicator cells (3 3 105 cells/well) in complete RPMI
medium in 24-well plates (Falcon, Becton Dickinson, NJ).
Medium was changed twice a week, and culture media
were assayed regularly for the presence of SIV proteins
by antigen capture enzyme-linked immunosorbent assay
(Thorstensson et al., 1991). Detection and quantification
of plasma SIV p27 antigen levels following SHIV chal-
lenge were performed by Innotest HIV antigen (Innoge-
netics N.V., Belgium), modified according to an assay
procedure for HIV-1 p24 detection (Lyamura et al., 1996).
Before detection of SIV p27 antigen, plasma was acid
and heat treated to dissociate immune complexes of SIV
antigen and antibodies. Polymerase chain reaction (PCR)
was performed in sera (Quesada-Rolander et al., 1996).
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